American Medical Systems' US prostate trial begins, Euro launch ahead:
This article was originally published in Clinica
American Medical Systems (AMS) has begun a phase I/II US trial of it AMS ProstaJect ethanol injection system for treating benign prostate hyperplasia (see Clinica No 942, p 22). The Minneapolis, Minnesota company expects to enrol patients from 13 US centres across the US. The transurethral device uses ethanol to ablate the cells of an enlarged prostate gland. AMS will launch the device in Europe this month.